Parexel and Palantir Technologies Inc. announced a multi-year strategic partnership to leverage AI to help enhance and accelerate the delivery of safe and effective clinical trials for the world?s biopharmaceutical customers. Under the collaboration, Parexel will leverage Palantir?s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the highest level of safety and regulatory rigor. Parexel is the first CRO working with Palantir in this capacity, building on the companies?

existing collaboration over the past year. Supported by Palantir?s industry-leading software, Parexel?s clinical data platform provides an integrated digital environment to hyper-automate manual processes, safely promote data discoverability, distill insights from historical trials and streamline coordination among scientific and operational teams and their partners. Incorporating Foundry and AIP into the Parexel environment will provide Parexel?s customers real-time access to high-quality validated data, ensuring transparency during studies in-flight and condensed timelines from trial planning to submission.